Literature DB >> 33208502

Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis.

Hendy Kristyanto1, Nienke J Blomberg1, Linda M Slot1, Ellen I H van der Voort1, Priscilla F Kerkman1,2, Aleida Bakker1, Leonie E Burgers1, Robin M Ten Brinck1, Annette H M van der Helm-van Mil1, Hergen Spits3,4, Dominique L Baeten5,6, Tom W J Huizinga1, René E M Toes1, Hans U Scherer7.   

Abstract

Autoreactive B cells mediate autoimmune pathology, but exactly how remains unknown. A hallmark of rheumatoid arthritis (RA), a common autoimmune disease, is the presence of disease-specific anticitrullinated protein antibodies (ACPAs). Here, we showed that ACPA-positive B cells in patients with RA strongly expressed T cell-stimulating ligands, produced abundant proinflammatory cytokines, and were proliferative while escaping inhibitory signals. This activated state was found at different degrees in different stages of disease: highest in patients with recent-onset RA, moderate in patients with established RA, and far less pronounced in ACPA-positive individuals "at risk" for developing disease. The activated autoreactive B cell response persisted in patients who achieved clinical remission with conventional treatment. ACPA-positive B cells in blood and synovial fluid secreted increased amounts of the chemoattractant interleukin-8, which attracted neutrophils, the most abundant immune cell in arthritic joints. Tetanus toxoid-specific B cells from the same patients exhibited properties of memory B cells without the activation and proliferation phenotype, but these cells transiently acquired a similar proliferative phenotype upon booster vaccination. Together, these data indicated that continuous antigenic triggering of autoreactive B cells occurs in human autoimmune disease and support the emerging concept of immunological activity that persists under treatment even in clinical remission, which may revise our current concept of treatment targets for future therapeutic interventions. In addition, our data pointed to a pathogenic role of ACPA-positive B cells in the inflammatory disease process underlying RA and favor approaches that aim at their antigen-specific inactivation or depletion.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33208502     DOI: 10.1126/scitranslmed.aaz5327

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  15 in total

Review 1.  The current status of anti-citrullinated protein antibodies and citrullinated protein-reactive B cells in the pathogenesis of rheumatoid arthritis.

Authors:  Jia He; JiYu Ju; XiaoDong Wang
Journal:  Mol Biol Rep       Date:  2021-12-02       Impact factor: 2.316

Review 2.  Microbiota-assisted therapy for systemic inflammatory arthritis: advances and mechanistic insights.

Authors:  Bowen Li; Bo Yang; Xiaoming Liu; Jianxin Zhao; R Paul Ross; Catherine Stanton; Hao Zhang; Wei Chen
Journal:  Cell Mol Life Sci       Date:  2022-08-06       Impact factor: 9.207

Review 3.  From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Diane van der Woude; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2022-05-23       Impact factor: 32.286

4.  Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression.

Authors:  Nida Meednu; Javier Rangel-Moreno; Fan Zhang; Katherine Escalera-Rivera; Elisa Corsiero; Edoardo Prediletto; Edward DiCarlo; Susan Goodman; Laura T Donlin; Soumya Raychauduri; Michele Bombardieri; Costantino Pitzalis; Dana E Orange; Andrew McDavid; Jennifer H Anolik
Journal:  Cell Rep       Date:  2022-05-03       Impact factor: 9.995

5.  Light chain skewing in autoantibodies and B-cell receptors of the citrullinated antigen-binding B-cell response in rheumatoid arthritis.

Authors:  Linda M Slot; Rochelle D Vergroesen; Priscilla F Kerkman; Ellen Staudinger; Sanne Reijm; Hugo J van Dooren; Ellen I H van der Voort; Tom W J Huizinga; René E M Toes; Hans U Scherer
Journal:  PLoS One       Date:  2021-03-30       Impact factor: 3.240

Review 6.  Neutrophils in chronic inflammatory diseases.

Authors:  Andrea Herrero-Cervera; Oliver Soehnlein; Ellinor Kenne
Journal:  Cell Mol Immunol       Date:  2022-01-17       Impact factor: 11.530

Review 7.  B Cells in Rheumatoid Arthritis:Pathogenic Mechanisms and Treatment Prospects.

Authors:  Fengping Wu; Jinfang Gao; Jie Kang; Xuexue Wang; Qing Niu; Jiaxi Liu; Liyun Zhang
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

8.  Antibodies to a Citrullinated Porphyromonas gingivalis Epitope Are Increased in Early Rheumatoid Arthritis, and Can Be Produced by Gingival Tissue B Cells: Implications for a Bacterial Origin in RA Etiology.

Authors:  Natalia Sherina; Charlotte de Vries; Nastya Kharlamova; Natalie Sippl; Xia Jiang; Boel Brynedal; Elin Kindstedt; Monika Hansson; Linda Mathsson-Alm; Lena Israelsson; Ragnhild Stålesen; Saedis Saevarsdottir; Rikard Holmdahl; Aase Hensvold; Gunnar Johannsen; Kaja Eriksson; Federica Sallusto; Anca I Catrina; Johan Rönnelid; Caroline Grönwall; Tülay Yucel-Lindberg; Lars Alfredsson; Lars Klareskog; Luca Piccoli; Vivianne Malmström; Khaled Amara; Karin Lundberg
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

Review 9.  Crosstalk between B cells and neutrophils in rheumatoid arthritis.

Authors:  Utsa Karmakar; Sonja Vermeren
Journal:  Immunology       Date:  2021-09-08       Impact factor: 7.397

10.  Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications.

Authors:  M Volkov; A S B Kampstra; K A van Schie; A Kawakami; M Tamai; S Kawashiri; T Maeda; T W J Huizinga; R E M Toes; D van der Woude
Journal:  Arthritis Res Ther       Date:  2021-12-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.